Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1422142/000156459018028092/arpo-10q_20180930.htm
SEC Filings
ARPO Annual Reports
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
ARPO Quarterly Reports
ARPO Corporate News
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales August 2021
Financial Exhibit
New Agreement August 2021
Vote of Security Holders August 2021
Earnings Release
Financial Exhibit August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders July 2021
Financial Exhibit
Regulated Disclosure June 2021
Earnings Release
Financial Exhibit May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales May 2021
Event for Officers
Financial Exhibit April 2021
Earnings Release
Financial Exhibit March 2021
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
August 2021
Financial Exhibit
New Agreement
New Agreement
August 2021
Vote of Security Holders
August 2021
Earnings Release
Financial Exhibit
Financial Exhibit
August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
July 2021
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
June 2021
Earnings Release
Financial Exhibit
Financial Exhibit
May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
May 2021
Event for Officers
Financial Exhibit
Financial Exhibit
April 2021
Earnings Release
Financial Exhibit
Financial Exhibit
March 2021
Last10K.com | 10-Q Quarterly Report Wed Nov 07 2018
Exhibit 99.1
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track
Conference Call and Webcast Today, November 7th at 8:30 a.m. EST
CINCINNATI — Nov. 7, 2018 — (
BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2018 and provided a business update.“Our TIME-2b clinical trial, evaluating the effect of AKB-9778, our first-in-class systemically administered Tie2 activator in patients with non-proliferative diabetic retinopathy (NPDR), is on track and we look forward to reporting top-line results in early Q2 2019,” commented Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. “In addition to the progress we’ve made with AKB-9778 for NPDR, we continue to advance a topical ocular formulation of AKB-9778 in open angle glaucoma and expect to initiate a Phase 1b study in Q2 2019. We are also excited about the potential of AKB-4924 (now known as GB004) and our partnership with Gossamer Bio, as announced in June. On the financial front, we remain well capitalized following the completion of a successful $52 million financing in June and receipt of the $20 million up front payment from our partnership with Gossamer.”
TIME-2b Study Overview
The TIME-2b study is a double-masked, placebo-controlled, multi-center trial evaluating the effect of AKB-9778 in patients with NPDR. 167 patients were randomized to receive 48 weeks of treatment with either AKB-9778 15 mg subcutaneously once daily (and placebo subcutaneously once daily), AKB-9778 15 mg subcutaneously twice daily, or placebo subcutaneously twice daily. The primary endpoint of the TIME-2b study is the percentage of patients who improve by 2 or more steps in diabetic retinopathy severity score (DRSS) in the study eye. One of our secondary objectives, the urine albumin to creatinine ratio or UACR, was prospectively included based on a post-hoc analysis of this biomarker in the TIME-2 Phase 2a clinical trial of AKB-9778 in diabetic macular edema. Initial results from this trial are expected early in the second quarter of 2019.
The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Wednesday, November 7, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aerpio Pharmaceuticals, Inc..
Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Statement Of Stockholders' Equity
Condensed Consolidated Statement Of Stockholders' Equity (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Income (Loss) (Unaudited)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Schedule Of Future Payments Related To Operating Leases (Detail)
Common Stock
Common Stock - Additional Information (Detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
License Agreement
License Agreement - Additional Information (Detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (Detail)
Net Income (Loss) Per Share Attributable To Common Stockholders
Net Income (Loss) Per Share Attributable To Common Stockholders (Tables)
Net Income (Loss) Per Share Attributable To Common Stockholders - Additional Information (Detail)
Net Income (Loss) Per Share Attributable To Common Stockholders - Schedule Of Computation Of Basic And Diluted Net Loss Per Share (Detail)
Net Income (Loss) Per Share Attributable To Common Stockholders - Schedule Of Reconciliation Of Numerator And Denominator Of The Basic And Diluted Net Income (Loss) Per Share (Detail)
Notes Payable To Investors
Notes Payable To Investors - Additional Information (Detail)
Preferred Stock
Preferred Stock - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Stock Options Valuation Assumptions (Detail)
Stock-Based Compensation - Summary Of Recognized Compensation Cost Related To Employee And Non-Employee Stock-Based Compensation Activity (Detail)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Detail)
Stock-Based Compensation - Summary Of Stock Option Activity (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Assets Measured On Recurring Basis (Detail)
Material Contracts, Statements, Certifications & more
Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ARPO
CIK: 1422142
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-028092
Submitted to the SEC: Wed Nov 07 2018 4:49:47 PM EST
Accepted by the SEC: Wed Nov 07 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/arpo/0001564590-18-028092.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...